THE
TIME
IS NOW

WE ARE AT A TIPPING POINT
FOR CANCER VACCINES.

1

We know the type of immune response needed, to kill cancer.

2

We know which parts of a cancer can stimulate the immune system.

3

New vaccine technology makes immunization
more effective.

THE VISION FOR A BREAST CANCER-FREE FUTURE

Vaccines may be the only way to kill every cancer cell and eliminate breast cancer.

Unlike a virus, which the immune system easily recognizes as an invader,
cancer arises from one’s own cells, mutating and proliferating.
It has evolved sophisticated ways of evading our immune systems.

For this reason, the immune system has trouble distinguishing cancer cells from healthy ones,
frequently failing to mount a big enough response, allowing cancer to spread undetected.

Over the past 20 years, doctors have found certain proteins, in breast cancers, are able to
trigger the immune system and even turn T-cells into cancer destroyers.

Vaccines mobilize our body’s own defenses.

PREVENTATIVE

Vaccines to intercept disease
and prevent cancer

PREVENTATIVE/THERAPEUTIC

Vaccines to intercept
and prevent recurrence

THERAPEUTIC/PREVENTATIVE

Vaccines to eliminate active disease
and prevent recurrence

STREAMLINING THE PROCESS

PINK ERASER PROJECT aims to move vaccines forward by funding and helping to quickly enroll trials for maximum efficiency. Often funding doesn't come quickly enough between the earliest phases and the time when large companies are assured a drug can be profitable.

PINK ERASER PROJECT
can change things by:

Building an active collaboration that bridges academia and industry, including scientists, patients, government agencies, foundations and biopharma

Streamlining existing trial platforms and facilitating communication to ensure a clear ‘roadmap’ to approvals

Informing patients and the public of the research and possibilities of a breast cancer vaccine, thereby creating a movement to revolutionize how we view women’s health and current, painful preventative surgeries and treatments…

Working with patient advocacy groups to enroll trials and ensure diverse patient populations, for the best outcomes.

HEAR FROM PEOPLE WHO HAVE
GOTTEN A BREAST CANCER VACCINE

FEATURED CASE STUDY

Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients with Breast Cancer

  • The vaccine was safe with 99% of patients with mild side effects similar to those of the flu vaccine

  • All 3 vaccine doses tested were effective in stimulating immunity

  • The middle dose was most effective – 80% of patients with advanced stage breast cancer are still alive 10+ years after vaccination

  • Even with the less immunogenic doses, 70% of advanced stage breast cancer patients are still alive 10+ years after vaccination

Disis et al, JAMA Oncology, 2022